Here are four notes:
1. The company named its cell therapy candidate for treating protruding and bulging lumbar disc disease, BRTX-100.
2. BRTX-100 is an autologous hypoxic cultured mesenchymal stem cell product.
3. The company will file an investigational new drug application with the FDA.
4. BioRestorative Therapies hopes to begin clinical trials for BRTX-100 this year.
More articles on spine:
13 statistics on neurosurgeon salary in 2016
5 notes on AANS’ new executive director Kathleen Craig
St. Rita’s Medical Center names Dr. Selvon St. Clair spine surgery director: 3 points
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
